Abstract
In longitudinal clinical trials, missing data are inevitable due to intercurrent events (ICEs) such as treatment interruption or premature discontinuation for different reasons. The COVID-19 pandemic has had substantial impact on clinical trials since early 2020 as it may result in missing data due to missed visits and premature discontinuations. The missing data due to COVID-19 can reasonably be assumed as missing at random (MAR). We propose a combined hypothetical strategy for sensitivity analyses to handle missing data due to both COVID-19 and non-COVID reasons. We modify the commonly used missing not at random (MNAR) methods, reference based imputation (RBI) and tipping point analysis, under this strategy. We propose the standard multiple imputation approach and derive an analytic likelihood based approach to implement the proposed methods to improve efficiency in applications. The proposed strategy and methods are applicable to a more general scenario when there are missing data due to both MAR and MNAR reasons.